DGAP-Ad hoc: aap Implantate AG

DGAP-Adhoc: aap Implantate AG: Annual financial statements 2015: Sales at EUR 28 million within the guidance and EBITDA KEUR 400 below the forecast

aap Implantate AG / Key word(s): Profit Warning/Final Results

22.04.2016 17:35

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

- EBITDA 2015 burdened by one-time value adjustment on inventories (KEUR 700) due to portfolio streamlining and potential cannibalization effects -

aap Implantate AG ("aap") recently signed a purchase agreement for the sale of all shares in its subsidiary aap Biomaterials GmbH and is currently working on the fulfillment of the conditions precedent in order to close the transaction. Upon closing of the transaction, aap becomes a pure player in trauma with a portfolio of IP-protected innovative technologies. Against this background and after an extensive feedback from customers in the first quarter of 2016 as well as due to the substantial expansion of the LOQTEQ(R) portfolio in the 2015 financial year, a cannibalization of standard trauma products by LOQTEQ(R) products may occur in future. In course of the focusing on the trauma business aap intends to sell the remaining 33% share in aap Joints GmbH (Recon products for knee, hip and shoulder) in 2016 and to discontinue its supplier activities in this non-core area. In order to adequately address the potential future sales risk for standard trauma products, and to take into account the decision in the context of aap Joints GmbH, the Management Board made in course of preparing the consolidated and annual financial statements 2015 an extraordinary and one-time value adjustment on inventories of standard trauma and recon products in the amount of KEUR 700. This value adjustment leads to a reduction in EBITDA in the 2015 financial year to the same extent. As a result, the EBITDA in the 2015 financial year amounts to EUR -1.9 million and is therefore KEUR 400 below the forecast made in November 2015 of EUR -1.5 million to EUR 1.0 million. The sales in the 2015 financial year amount to EUR 28.0 million and are therefore within the guidance of EUR 27.5 million and EUR 31.5 million.

Contact: aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; f.franke@aap.de

22.04.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

--------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------